Fatemeh Amrollahi

Fatemeh Amrollahi

Auto-generated profile, based on publicly available information

Fatemeh Amrollahi

Department of Biomedical Data Science, Stanford University, Palo Alto, CA, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2025 in NEJM AI
Verified
Journal Article
Closed access
YSYuki Sahashi
Yuki Sahashi
MVMilos Vukadinovic
Milos Vukadinovic
FAFatemeh Amrollahi
Fatemeh Amrollahi
Hirsh D. TrivediHirsh D. Trivedi
Hirsh D. Trivedi
JRJustin Rhee
Justin Rhee
AKAlan C. Kwan
Alan C. Kwan
Chronic liver disease (CLD) affects more than 1.5 billion adults, most of whom are asymptomatic and undiagnosed. Echocardiography is broadly performed and visualizes the liver, but this information is not clinically leveraged for CLD diagnosis. We developed and evaluated EchoNet-Liver, a deep-learning, computer-vision pipeline that can identify high-quality subcostal images from full echocardiogram studies and detect the presence of cirrhosis and steatotic liver disease (SLD). This retrospective observational study included adult patients from two large urban academic medical centers who received both echocardiography and abdominal imaging — either ultrasound or magnetic resonance imaging (MRI) — within 30 days. The model predictions were compared with diagnoses from clinical evaluations of paired abdominal ultrasound or MRI studies. A total of 1,596,640 echocardiogram videos from 66,922 studies and 24,276 patients at Cedars–Sinai Medical Center (CSMC) were used to develop EchoNet-Liver. In a held-out CSMC test cohort, EchoNet-Liver detected cirrhosis with an area under the receiver operating characteristic curve (AUROC) of 0.837 (95% confidence interval [CI], 0.828 to 0.848) and SLD with an AUROC of 0.799 (95% CI, 0.788 to 0.811). In a separate test cohort with paired abdominal MRI studies, EchoNet-Liver detected cirrhosis with an AUROC of 0.704 (95% CI, 0.699 to 0.708) and SLD with an AUROC of 0.725 (95% CI, 0.707 to 0.762). In an external test cohort of 106 patients (5280 videos), the model detected cirrhosis with an AUROC of 0.830 (95% CI, 0.799 to 0.859) and SLD with an AUROC of 0.769 (95% CI, 0.733 to 0.813). Deep-learning assessment of clinical echocardiography enables opportunistic screening for SLD and cirrhosis. The application of this algorithm can identify patients who may benefit from further diagnostic testing and treatment for CLD. (Funded by KAKENHI [Japan Society for the Promotion of Science, 24K10526] and others.)

23 June 2026 in NEJM AI
Verified
Journal Article
Closed access
ALApril S. Liang
April S. Liang
FAFatemeh Amrollahi
Fatemeh Amrollahi
YJYixing Jiang
Yixing Jiang
CCConor K. Corbin
Conor K. Corbin
GKGrace Y. E. Kim
Grace Y. E. Kim
JCJonathan H. Chen
Jonathan H. Chen
Repetitive laboratory testing that is unlikely to yield clinically useful information is a common practice that burdens patients and increases health care costs. Education and feedback interventions have limited success, while general test ordering restrictions and electronic alerts impede appropriate clinical care. We introduce and evaluate SmartAlert, a machine learning–driven clinical decision support (CDS) system integrated into the electronic health record that predicts stable laboratory results to reduce unnecessary repeat testing. This Case Study describes the implementation process, challenges, and lessons learned from deploying SmartAlert targeting complete blood count (CBC) utilization in a randomized controlled pilot across 9270 admissions in eight acute care units across two hospitals between August 15, 2024, and March 15, 2025. The results show a significant decrease in the number of CBC results within 52 hours of SmartAlert display (1.54 vs. 1.82; P<0.01) without adverse effect on secondary safety outcomes, representing a 15% relative reduction in repetitive testing. Implementation lessons learned include interpretation of probabilistic model predictions in clinical contexts, stakeholder engagement to define acceptable model behavior, governance processes for deploying a complex model in a clinical environment, user interface design considerations, alignment with clinical operational priorities, and the value of qualitative feedback from end users. In conclusion, a machine learning–driven CDS system backed by a deliberate implementation and governance process can provide precision guidance on inpatient laboratory testing to safely reduce unnecessary repetitive testing. (Funded by the Agency for Science, Technology, and Research and others.)

4 March 2026 in medRxiv
Verified
Preprint
Open access
PDF file
NMNicholas P. Marshall
Nicholas P. Marshall
WCWenyuan Chen
Wenyuan Chen
FAFatemeh Amrollahi
Fatemeh Amrollahi
FHFateme Nateghi Haredasht
Fateme Nateghi Haredasht
MMManoj V. Maddali
Manoj V. Maddali
JCJonathan H Chen
Jonathan H Chen
Background: The 2024 blood culture bottle shortage brought diagnostic resource allocation to the forefront, reflecting persistent, foundational challenges with low-value testing and empiric treatment approaches under clinical uncertainty. Objective: To determine whether a machine learning approach using electronic medical record data can predict bacteremia more effectively than existing systems and practices to guide diagnostic testing and empiric treatment strategies. Methods: In a retrospective cohort of 101,812 adult emergency department encounters (2015-2025), we first established an idealized cognitive baseline by evaluating physician and generative AI (GPT-5) application of the professional society-endorsed Fabre framework on a validation subset. We then trained an XGBoost model (Cultryx) on the full cohort to predict bacteremia, benchmarking its performance against real-world clinical heuristics (SIRS, Shapiro Rule). Results: For the idealized baseline, physicians applying the Fabre framework achieved 95.7% sensitivity, but GPT-5 automation failed to replicate this standard (71.6% sensitivity). In real-world benchmarking, Cultryx outperformed all clinical heuristics (AUROC 0.810). SIRS lacked specificity (41.2%), driving diagnostic overuse, while the Shapiro Rule lacked sensitivity (70.2%), missing ~30% of bacteremia cases. In contrast, when calibrated to a strict 95% sensitivity target, Cultryx achieved the highest culture volume deferral rate (26.2%, deferring ~ 15,872 bottles with predicted negative results) while maintaining a 98.9% negative predictive value. Cultryx score , a simplified bedside tool, retained a 20.8% deferral rate. Conclusions: Machine learning provides a superior, data-driven alternative to mainstream clinical heuristics for predicting bacteremia. By maximizing culture deferment without compromising pathogen detection, Cultryx can conserve diagnostic resources, reduce unnecessary empiric antibiotic exposure, and systematically elevate patient safety. Summary: Cultryx, a machine learning model for blood culture stewardship, outperforms standard clinical heuristics in predicting bacteremia. This approach could reduce culture utilization by over 26% while preserving pathogen detection, conserving diagnostic resources, reducing unnecessary antibiotic exposure, and elevating patient safety.

18 July 2025 in Journal of Hospital Medicine
Verified
Journal Article
Closed access
RLRebecca Y. Linfield
Rebecca Y. Linfield
LMLeon S. Moskatel
Leon S. Moskatel
SCSean Carlton
Sean Carlton
FAFatemeh Amrollahi
Fatemeh Amrollahi
DEDavid Epstein
David Epstein
LSLisa Shieh
Lisa Shieh